Literature DB >> 18096277

Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune responses of peptides derived from V antigen of Yersinia pestis.

Arif Azam Khan1, Jaya Prakash Babu, Geetanjali Gupta, D N Rao.   

Abstract

Yersinia pestis is a Gram negative bacterium which causes bubonic and pneumonic plague. Out of the two protective antigens F1 and V as vaccine candidates, we focused our attention on V antigen as peptide-based immunogen. Eleven peptides of varying lengths were synthesized for mapping major antigenic sites on V antigen. Six peptides showed competition by three complimentary approaches (1) with anti-V sera, (2) with anti-peptide sera and (3) by direct binding assay. Peptides which showed competition were found to be highly immunogenic in terms of peak antibody titres (both IgG and IgA) with longer duration, showed predominantly IgG2a/IgG2b subclass distribution, high affinity/avidity indices with single immunization schedule through intranasal routes. After intranasal immunization, these peptides showed high IgA response in sera and SIgA in intestinal washes and bronchoalveolar lavages while intramuscular immunization failed to give mucosal response. Intramuscular immunization generated high titre antibodies (both IgG and IgA) in sera with negligible SIgA response in washes which required additional booster immunization. All the peptides sera reacted with V antigen in Western blot analysis. During T cell proliferation assay, five peptides showed lymphocyte proliferation response irrespective of how antigen priming and pulsing was done in three strains of mice. These five peptides also showed Th1 cytokine profile whereas rest of the peptides showed mixed Th1/Th2 response. Two peptides exclusively showed high levels of IL-10 production. Mathematical modeling of V antigen indicates that these peptides lie on the surface of the protein. In conclusion, peptides a, g and j are pure B cell epitopes; peptides d and k are pure T cell epitopes and peptides b, f and i showed both B and T cells property on V antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18096277     DOI: 10.1016/j.vaccine.2007.11.028

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles.

Authors:  Jayaprakash Babu Uppada; Arif Azam Khan; Ajaz Ahmad Bhat; Ranjana Deshmukh; Donthamsetty Nageswara Rao
Journal:  Med Microbiol Immunol       Date:  2009-09-25       Impact factor: 3.402

3.  Amino acid and structural variability of Yersinia pestis LcrV protein.

Authors:  Andrey P Anisimov; Svetlana V Dentovskaya; Evgeniy A Panfertsev; Tat'yana E Svetoch; Pavel Kh Kopylov; Brent W Segelke; Adam Zemla; Maxim V Telepnev; Vladimir L Motin
Journal:  Infect Genet Evol       Date:  2009-10-14       Impact factor: 3.342

4.  Fine-tuning synthesis of Yersinia pestis LcrV from runaway-like replication balanced-lethal plasmid in a Salmonella enterica serovar typhimurium vaccine induces protection against a lethal Y. pestis challenge in mice.

Authors:  Ascención Torres-Escobar; María Dolores Juárez-Rodríguez; Bronwyn M Gunn; Christine G Branger; Steven A Tinge; Roy Curtiss
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

5.  Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice.

Authors:  Julie A Musson; Rebecca Ingram; Guillaume Durand; Stephanie Ascough; Emma L Waters; M Gillian Hartley; Timothy Robson; Bernard Maillere; E Diane Williamson; Shiranee Sriskandan; Daniel Altmann; John H Robinson
Journal:  Infect Immun       Date:  2010-07-26       Impact factor: 3.441

6.  Amino acid substitutions in LcrV at putative sites of interaction with Toll-like receptor 2 do not affect the virulence of Yersinia pestis.

Authors:  Wei Sun; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-07-24       Impact factor: 3.738

7.  High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.

Authors:  Bei Li; Lei Zhou; JingYu Guo; Xiaoyi Wang; Bin Ni; Yuehua Ke; Ziwen Zhu; Zhaobiao Guo; Ruifu Yang
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

Review 8.  Immune defense against pneumonic plague.

Authors:  Stephen T Smiley
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.

Authors:  Karina Ramirez; Alejandra V E Capozzo; Scott A Lloyd; Marcelo B Sztein; James P Nataro; Marcela F Pasetti
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

10.  Polymorphism in the Yersinia LcrV Antigen Enables Immune Escape From the Protection Conferred by an LcrV-Secreting Lactococcus Lactis in a Pseudotuberculosis Mouse Model.

Authors:  Catherine Daniel; Amélie Dewitte; Sabine Poiret; Michaël Marceau; Michel Simonet; Laure Marceau; Guillaume Descombes; Denise Boutillier; Nadia Bennaceur; Sébastien Bontemps-Gallo; Nadine Lemaître; Florent Sebbane
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.